Jay Venkatesan - Jun 28, 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role
Director
Signature
/s/ Jay Venkatesan
Stock symbol
ELTX
Transactions as of
Jun 28, 2024
Transactions value $
$998,000
Form type
4
Date filed
7/2/2024, 09:53 PM
Previous filing
Dec 29, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Common Warrants Purchase $0 +50K $0.00 50K Jun 28, 2024 Common Stock 50K $5.00 Direct F1, F2
transaction ELTX Pre-Funded Warrants Purchase $250K +50K $4.99 50K Jun 28, 2024 Common Stock 50K $0.01 Direct F3, F4
transaction ELTX Common Warrants Purchase $0 +50K $0.00 50K Jun 28, 2024 Common Stock 50K $5.00 See footnote F1, F2, F5
transaction ELTX Pre-Funded Warrants Purchase $250K +50K $4.99 50K Jun 28, 2024 Common Stock 50K $0.01 See footnote F3, F4, F5
transaction ELTX Common Warrants Purchase $0 +50K $0.00 50K Jun 28, 2024 Common Stock 50K $5.00 See footnote F1, F2, F5
transaction ELTX Pre-Funded Warrants Purchase $250K +50K $4.99 50K Jun 28, 2024 Common Stock 50K $0.01 See footnote F3, F4, F5
transaction ELTX Common Warrants Purchase $0 +50K $0.00 50K Jun 28, 2024 Common Stock 50K $5.00 See footnote F1, F2, F5
transaction ELTX Pre-Funded Warrants Purchase $250K +50K $4.99 50K Jun 28, 2024 Common Stock 50K $0.01 See footnote F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F2 The Common Warrants expire on July 1, 2029.
F3 Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F4 The Pre-Funded Warrants do not have an expiration date.
F5 The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any.